These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc). Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235 [TBL] [Abstract][Full Text] [Related]
4. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Carithers RL; Emerson SS Hepatology; 1997 Sep; 26(3 Suppl 1):83S-88S. PubMed ID: 9305670 [TBL] [Abstract][Full Text] [Related]
5. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Farrell GC; Bacon BR; Goldin RD Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453 [TBL] [Abstract][Full Text] [Related]
9. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371 [TBL] [Abstract][Full Text] [Related]
10. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. Schvarcz R; Ando Y; Sönnerborg A; Weiland O J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289 [TBL] [Abstract][Full Text] [Related]
11. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876 [TBL] [Abstract][Full Text] [Related]
13. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment]. Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775 [TBL] [Abstract][Full Text] [Related]
14. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Manesis EK; Papaioannou C; Gioustozi A; Kafiri G; Koskinas J; Hadziyannis SJ Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505 [TBL] [Abstract][Full Text] [Related]
15. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667 [TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. Diago M; Suárez D; García-Villarreal L; Castro A; Domínguez A; Pardo M; del Olmo JA; Pérez-Hernández F; Aguilar J; Quiroga JA; Carreño V J Med Virol; 2001 Aug; 64(4):460-5. PubMed ID: 11468730 [TBL] [Abstract][Full Text] [Related]
17. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984 [TBL] [Abstract][Full Text] [Related]
18. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995 [TBL] [Abstract][Full Text] [Related]
19. Therapy of hepatitis C: alpha interferon and ribavirin. Reichard O; Schvarcz R; Weiland O Hepatology; 1997 Sep; 26(3 Suppl 1):108S-111S. PubMed ID: 9305674 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Poynard T; Leroy V; Cohard M; Thevenot T; Mathurin P; Opolon P; Zarski JP Hepatology; 1996 Oct; 24(4):778-89. PubMed ID: 8855176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]